Aprea Therapeutics, Inc. (APRE) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Boston, MA, 美国. 现任CEO为 Oren Gilad.
APRE 拥有 IPO日期为 2019-10-03, 8 名全职员工, 在 NASDAQ Global Select, 市值为 $6.12M.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
